Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Wins Brazilian Trastuzumab and Rituximab Tender

As Company Aims to Lead Latin American Biosimilar Market

Executive Summary

Celltrion has won a Brazilian tender to supply two oncology biosimilars – Herzuma (trastuzumab) and Truxima (rituximab) – to the Brazilian market. Based on its successful bid in Brazil, the company plans on expanding its direct sales business model to Peru and Chile in the third quarter of this year.

You may also be interested in...



Celltrion Recovers With High-Margin US Sales

South Korea’s Celltrion has delivered a strong second quarter on the back of high-margin US sales, as its Truxima rituximab biosimilar recovered. The company is on track to launch at least one biosimilar every year by 2030. Meanwhile, the company and partner Icure have filed a donepezil patch with the Korean Ministry of Food and Drug Safety.

Celltrion Views Brazilian Approval As Gateway Into Latin America

Celltrion and its local marketing partner Biomm are working to bring biosimilar trastuzumab to the Brazilian market after receiving approval from local medicines agency Anvisa. A rituximab authorization could soon follow.

US Bill Would Create Emergency API Stockpile

US representatives Abigail Spanberger and David McKinley have introduced bipartisan legislation to create an emergency supply of active ingredients used in vital generics and to incentivize domestic manufacturing of these ingredients. The move has garnered support from many industry leaders.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel